Assessment of sustained effects of levosimendan on right ventricular systolic functions in patients with advanced heart failure.
A K
AK
Mansiroglu
E
E
Oner
M
M
Erturk
H
H
Karakurt
M U
MU
Somuncu
A
A
Birant
A K
AK
Kalkan
D
D
Ozturk
A
A
Eksik
D000368:Aged; D001682:Biological Availability; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D018450:Disease Progression; D015150:Echocardiography, Doppler / Q000379:methods; D005260:Female; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000503:physiopathology; D006801:Humans; D006835:Hydrazones / Q000008:administration & dosage / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D011724:Pyridazines / Q000008:administration & dosage / Q000493:pharmacokinetics; D000077464:Simendan; D016896:Treatment Outcome; D016278:Ventricular Function, Right / Q000187:drug effects
D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D000077464:Simendan
Levosimendan; acute heart failure; isovolumic acceleration; right ventricle